TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Group, Inc. (Nasdaq: TMDX), a medical technology company focusing on organ transplant therapy, has announced the granting of inducement awards to four new employees. The grants, approved by the Compensation Committee and in line with Nasdaq Listing Rule 5635(c)(4), include:
- 3,073 non-qualified stock options with an exercise price of $170.28 per share
- 2,003 restricted stock units
The stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary and the remainder monthly over three years. The restricted stock units will vest 25% annually over four years. Both are subject to continued employment and the terms of the TransMedics Group, Inc. Inducement Plan.
TransMedics Group, Inc. (Nasdaq: TMDX), un'azienda di tecnologia medica che si concentra sulla terapia del trapianto d'organo, ha annunciato l'assegnazione di premi di inducimento a quattro nuovi dipendenti. I premi, approvati dal Comitato di Compensazione e in linea con la Regola di Quotazione Nasdaq 5635(c)(4), includono:
- 3.073 opzioni su azioni non qualificate con un prezzo di esercizio di $170,28 per azione
- 2.003 unità di azioni vincolate
Le opzioni su azioni hanno un termine di 10 anni e matureranno in quattro anni, con il 25% che matura al primo anniversario e il resto mensilmente per tre anni. Le unità di azioni vincolate matureranno 25% annualmente per quattro anni. Entrambi sono soggetti a un impiego continuato e ai termini del Piano di Inducimento di TransMedics Group, Inc.
TransMedics Group, Inc. (Nasdaq: TMDX), una empresa de tecnología médica centrada en la terapia de trasplante de órganos, ha anunciado la concesión de premios de inducción a cuatro nuevos empleados. Las concesiones, aprobadas por el Comité de Compensación y de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4), incluyen:
- 3.073 opciones sobre acciones no calificadas con un precio de ejercicio de $170.28 por acción
- 2.003 unidades de acciones restringidas
Las opciones sobre acciones tienen un período de 10 años y se adquirirán a lo largo de cuatro años, con el 25% adquiriéndose en el primer aniversario y el resto mensualmente durante tres años. Las unidades de acciones restringidas se adquirirán 25% anualmente durante cuatro años. Ambas están sujetas a empleo continuado y a los términos del Plan de Inducción de TransMedics Group, Inc.
TransMedics Group, Inc. (Nasdaq: TMDX)는 장기 이식 치료에 집중하는 의학 기술 회사로서 네 명의 신입 직원에게 유인 보상을 지급한다고 발표했습니다. 이 보상은 보상위원회의 승인을 받았으며 Nasdaq 상장 규정 5635(c)(4)에 따릅니다. 내용은 다음과 같습니다:
- 3,073개의 비자격 주식 옵션으로, 주당 행사 가격은 $170.28입니다.
- 2,003개의 제한주식 단위
주식 옵션은 10년 기준으로, 4년 동안 분할됩니다. 첫 번째 기념일에 25%가 분할되고, 나머지는 3년 동안 매월 분할됩니다. 제한주식 단위는 4년 동안 매년 25%가 분할됩니다. 두 가지 모두 지속적인 고용과 TransMedics Group, Inc.의 유인 계획 조건에 따릅니다.
TransMedics Group, Inc. (Nasdaq: TMDX), une entreprise de technologie médicale axée sur la thérapie de transplantation d'organes, a annoncé l'octroi de récompenses d'incitation à quatre nouveaux employés. Les récompenses, approuvées par le Comité de Rémunération et conformément à la Règle de Cotation Nasdaq 5635(c)(4), comprennent :
- 3.073 options d'achat d'actions non qualifiées avec un prix d'exercice de 170,28 $ par action
- 2.003 unités d'actions restreintes
Les options d'achat d'actions ont une durée de 10 ans et seront acquises sur quatre ans, avec 25% acquises à la première anniversaire et le reste mensuellement pendant trois ans. Les unités d'actions restreintes seront acquises 25% chaque année pendant quatre ans. Les deux sont soumises à un emploi continu et aux conditions du Plan d'Incitation de TransMedics Group, Inc.
TransMedics Group, Inc. (Nasdaq: TMDX), ein Medizintechnikunternehmen, das sich auf die Therapie von Organtransplantationen konzentriert, hat die Gewährung von Anreizleistungen an vier neue Mitarbeiter bekannt gegeben. Die Zuwendungen, genehmigt durch den Vergütungsausschuss und in Übereinstimmung mit der Nasdaq-Listenregel 5635(c)(4), umfassen:
- 3.073 nicht qualifizierte Aktienoptionen mit einem Ausübungspreis von $170,28 pro Aktie
- 2.003 eingeschränkte Aktieneinheiten
Die Aktienoptionen haben eine Laufzeit von 10 Jahren und erwerben sich über vier Jahre, wobei 25% beim ersten Jahrestag und der Rest monatlich über drei Jahre erworben werden. Die eingeschränkten Aktieneinheiten werden 25% jährlich über vier Jahre erworben. Beide unterliegen der fortgesetzten Anstellung und den Bedingungen des Anreizplans von TransMedics Group, Inc.
- Attracting new talent with stock-based compensation
- Aligning employee interests with company performance through equity grants
- Potential dilution of existing shareholders' equity
TransMedics granted non-qualified stock options to purchase 3,073 shares of TransMedics' common stock and 2,003 restricted stock units in the aggregate. The stock options were granted with a per share exercise price of
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in
Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302226643.html
SOURCE TransMedics Group, Inc.
FAQ
How many employees received inducement grants from TransMedics (TMDX) on August 16, 2024?
What types of inducement grants did TransMedics (TMDX) issue on August 16, 2024?
What was the exercise price for the stock options granted by TransMedics (TMDX) on August 16, 2024?
What is the vesting schedule for the stock options granted by TransMedics (TMDX) on August 16, 2024?
